Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 1Carcinoma, Hepatocellular 1Cancer Pain 1Breast Neoplasms 1Breakthrough Pain 1

Interventions

Transcutaneous Electric Nerve Stimulation 3Acupuncture Therapy 3Transcranial Direct Current Stimulation 2Pharmaceutical Services 2Morphine 2Control Groups 2Analgesics, Opioid 2nabiximols 1Tramadol 1Therapeutic Touch 1Telemedicine 1Surveys and Questionnaires 1Spinal Cord Stimulation 1Sodium Bicarbonate 1Ropivacaine 1Radiosurgery 1Radiofrequency Ablation 1Radiation 1Pregabalin 1Patient Education as Topic 1Passive Cutaneous Anaphylaxis 1Myofascial Release Therapy 1Methods 1Lidocaine 1Laser Therapy 1Infusions, Intravenous 1Imagery, Psychotherapy 1Hospitals 1GluN2C-2D antagonist UBP145 1Ethanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Cancer Pain × Infusions, Intravenous × Clear all
NCT05053308 2023-08-07

Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement

Seoul National University

Phase NA Withdrawn

Cancer Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡